HIGHLIGHTS

1825 Selected Articles from This Issue

SPECIAL FEATURES

CCR Translations

1827 Atezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma
Florian Castet, Catherine E. Willoughby, Philipp K. Haber, and Josep M. Llovet
See related article, p. 1836

1830 Pressurized Intraperitoneal Aerosol Chemotherapy: The Road from Promise to Proof
Loek A.W. de Jong, Nielska P. van Erp, and Lana Bijelic
See related article, p. 1875

1833 Morning for Irofulven, What Could be fîNER?
Haoyang Jiang and Roger A. Greenberg

CCR Drug Updates

1836 FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma
See related commentary, p. 1827

1842 FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer

1850 FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

RESEARCH BRIEFS: CLINICAL TRIAL BRIEF REPORTS

1855 Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer
Giulia Petroni, Aitziber Buqué, Takahiro Yamazaki, Norma Bloy, Maurizio Di Liberto, Selina Chen-Kiang, Silvia C. Formenti, and Lorenzo Galluzzi

CLINICAL TRIALS: TARGETED THERAPY

1864 Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor
David S. Hong, Kathleen N. Moore, Johanna C. Bendell, Daniel D. Karp, Judy S. Wang, Susanna V. Ulahannan, Suzanne Jones, Wenjuan Wu, Gregory P. Donoho, Yan Ding, Andrew Capen, Xuejing Wang, Aimee Bence Lin, and Manish R. Patel
TABLE OF CONTENTS

1875  PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases

Guowei Kim, Hon Lyn Tan, Raghad Sundar, Bettina Lieske, Cheng Ean Chee, Jingshan Ho, Asim Shabhir, Maria V. Babak, Wei Han Ang, Boon Cher Goh, Wei Peng Yong, Lingzhi Wang, and Jimmy B.Y. So

See related commentary, p. 1830

1882  Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE)

Simon J. Crabb, Sarah Danson, James W.F. Catto, Syed Hussain, Danna Chan, Denise Dunkley, Nichola Downs, Ellice Marwood, Laura Day, Geoff Saunders, Michelle Light, Amy Whitehead, Deborah Ellis, Naveed Sarwar, Deborah Enting, Alison Birile, Bernadette Johnson, Robert Huddart, and Gareth Griffiths

1893  Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies

Mina M. Tayari, Helena G. Dos Santos, Deukwoo Kwon, Terrence J. Bradley, Amber Thomassen, Charles Chen, Yvonne Dinh, Aymee Perez, Arthur Zelent, Lluis Morey, Luisa Cimmino, Ramin Shiekhattar, Ronan T. Swords, and Justin M. Watts

CLINICAL TRIALS: IMMUNOTHERAPY

1904  Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors

Kryiakos P. Papadopoulos, Karen Autio, Talia Golan, Konstantin Dobrenkov, Elliot Chartash, Qiuseng Chen, Richard Wnek, and Georgina V. Long

1912  Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma

David W. Andrews, Kevin D. Judy, Charles B. Scott, Samantha Garcia, Larry A. Harshyne, Lawrence Kenyon, Kiran Talekar, Adam Flanders, Kofi-Buaku Atsina, Lyndon Kim, Nina Martinez, Wenyin Shi, Maria Werner-Wasik, Haisong Liu, Mikhail Prosnik, Mark Curtis, Rhonda Kean, Donald Y. Ye, Emily Bongiorno, Sami Sauma, Mark A. Exley, Kara Pigott, and D. Craig Hooper

1923  Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10

Zev A. Wainberg, Charles S. Fuchs, Josep Tabernero, Kohei Shitara, Kei Muro, Eric Van Cutsem, Yung-Jue Bang, Hyun Cheol Chung, Kensei Yamaguchi, Eniko Varga, Jen-Shi Chen, Daniel Hochhauser, Peter Thuss-Patience, Salah-Eddin Al-Batran, Marcelo Garrido, Uma Kher, Chie-Schin Shih, Sukrut Shah, Pooja Bhagia, and Joseph Chao

PRECISION MEDICINE AND IMAGING

1932  PET Imaging of TIGIT Expression on Tumor-Infiltrating Lymphocytes

Travis Shaffer, Arutselvan Natarajan, and Sanjiv S. Gambhir

1941  Diffusion-weighted Imaging Allows for Downgrading MR BI-RADS 4 Lesions in Contrast-enhanced MRI of the Breast to Avoid Unnecessary Biopsy

Paola Clauser, Barbara Krug, Hubert Bickel, Matthias Dietzel, Katja Pinker, Victor-Frederic Neuhaus, Maria Adele Marino, Marco Moschetta, Nicoletta Troiano, Thomas H. Helbich, and Pascal A.T. Baltzer

1949  Changes in Diffuse Optical Tomography Images During Early Stages of Neoadjuvant Chemotherapy Correlate with Tumor Response in Different Breast Cancer Subtypes

Mirella L. Altoe, Kevin Kalinsky, Alessandro Marone, Hyun K. Kim, Hua Guo, Hanina Hibshoosh, Mariella Tejada, Katherine D. Crew, Melissa K. Accordino, Meghna S. Trivedi, Dawn L. Hershman, and Andreas H. Hielscher

1958  Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [55Cu]Cu-NOTA-anti-CD8 PET

Veronica L. Nagle, Kelly E. Henry, Charli Ann J. Hertz, Maya S. Graham, Carl Campos, Luis F. Parada, Neeta Pandit-Taskar, Andrea Schietinger, Ingo K. Mellinghoff, and Jason S. Lewis

1967  Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)

1974 VLA4-Targeted Nanoparticles Hijack Cell Adhesion-Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival

Francesca Fontana, Michael J. Scott, John S. Allen, Xiaoxia Yang, Grace Cui, Dianpan Pan, Noriko Yanaba, Mark A. Fiala, Julie O’Neal, Anne H. Schmieder-Atteberry, Julie Ritchey, Michael Rettig, Kathleen Simons, Steven Fletcher, Ravi Vij, John F. DiPersio, and Gregory M. Lanza

1987 Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry

Sandra Martinez-Morilla, Franz Villarroel-Espindola, Pok Fai Wong, Maria I. Toki, Thazin Nwe Aung, Vasiliki Pelekanou, Brian Bourke-Martin, Kurt A. Schalper, Harriet M. Kluger, and David L. Rimm

1997 Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer

Sabine Topka, Zoe Steinsnyder, Vignesh Ravichandran, Kaitlyn Tkachuk, Yelena Kemel, Chaitanya Bandlamudi, Mogens Winkel Madsen, Helena Furberg, Ouathek Ouerfelli, Charles M. Rudin, Gopa Iyer, Steven M. Lipkin, Semanti Mukherjee, Elisa de Stanchina, Joseph Vijai, and Kenneth Offit

See related commentary, p. 1833

2011 Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer

Judit Börcsök, Zsofia Sztpiszski, Raie Bekele, Szízhi P. Gao, Miklos Diossy, Amruta S. Samant, Kasia M. Dillon, Viktoria Tisza, Michael A. Vogelbaum, Peter E. Fecci, and Justin D. Lathia

See related commentary, p. 1833

2023 Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer

Nina G. Steele, Giulia Biffi, Samantha B. Kemp, Yaqing Zhang, Donovan Drouillard, Lilyun Syu, Yuan Hao, Tobiyoda E. Oni, Erin Brosman, Xiaoxia Yang, Grace Cui, Dianpan Pan, Noriko Yanaba, Mark A. Fiala, Julie O’Neal, Anne H. Schmieder-Atteberry, Julie Ritchey, Michael Rettig, Kathleen Simons, Steven Fletcher, Ravi Vij, John F. DiPersio, and Gregory M. Lanza

2038 Preclinical Modeling of Surgery and Steroid Therapy for Glioblastoma Reveals Changes in Immunophenotype that are Associated with Tumor Growth and Outcome


2050 PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates


2061 LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors

Kelli-Ann Monaco, Scott Delach, Jing Yuan, Yuji Mishina, Paul Fordjour, Emma Labrot, Daniel McKay, Ribo Guo, Stacy Higgins, Hui Qin Wang, Jinsheng Liang, Karen Bui, John Green, Peter Aspesi, Jessi Ambrose, Felipe Mapa, Lesley Griner, Mariela Jaskelioff, John Fuller, Kenneth Crawford, Gwenn Pardee, Stephanie Widge, Peter S. Hammerman, Jeffrey A. Engelman, Darrin D. Stuart, Vesselina G. Cooke, and Giordano Caponigro

See related commentary, p. 1833
### TABLE OF CONTENTS

2074 Clinical Proteomics of Metastatic Melanoma Reveals Profiles of Organ Specificity and Treatment Resistance  
Lir Beck, Michal Harel, Shun Yu, Ettai Markovits, Ben Boursi, Gal Markel, and Tamar Geiger

2087 Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells  
Wenting Pan, Zhouwei Zhang, Hannah Kimball, Fangfang Qu, Kyler Berlind, Konrad H. Stopsack, Gwo-Shu Mary Lee, Toni K. Choueiri, and Philip W. Kantoff

2100 A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer  
AC Alex Cazes, Oscar Betancourt, Edgar Esparza, Evangeline S. Mose, Dawn Jaquish, Eric Wong, Alexis A. Wascher, Hervé Tiriac, Marco Gymnopoulos, and Andrew M. Lowy

2111 Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001  

### LETTERS TO THE EDITOR

2119 Outcomes of Oral Vinorelbine in Progressive Desmoid Fibromatosis—Letter  
AC Chuanxi Zheng, Li Min, and Chongqi Tu

2120 Outcomes of Oral Vinorelbine in Progressive Desmoid Fibromatosis—Response  
Olivier Mir, Charles Honoré, Ali N. Chamseddine, Matthieu Faron, Leila Haddag-Miliani, Arnaud Bayle, and Axel Le Cesne

### ABOUT THE COVER

The cover shows a section of pancreatic cancer precursor lesions in a mouse model of this disease expressing oncogenic Kras and the Sonic Hedgehog ligand. Gomori trichrome stain shows collagen deposition in blue, cell nuclei in dark purple, and cell cytoplasm in pink. For details, see the article by Steele and colleagues on page 2023 of this issue.